Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.,JAMA Neurology

当前位置： X-MOL 学术 › JAMA Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome.
JAMA Neurology ( IF 20.4 ) Pub Date : 2023-04-03 , DOI: 10.1001/jamaneurol.2023.0488
Lawren VandeVrede ₁ , Renaud La Joie _{1,

2} , Elisabeth H Thijssen ₃ , Breton M Asken ₄ , Stephanie A Vento ₁ , Torie Tsuei ₁ , Suzanne L Baker ₂ , Yann Cobigo ₁ , Corrina Fonseca ₁ , Hilary W Heuer ₁ , Joel H Kramer ₁ , Peter A Ljubenkov ₁ , Gil D Rabinovici _{1,

5} , Julio C Rojas ₁ , Howie J Rosen ₁ , Adam M Staffaroni ₁ , Brad F Boeve ₆ , Brad C Dickerson ₇ , Murray Grossman ₈ , Edward D Huey _{9,

10} , David J Irwin ₇ , Irene Litvan ₁₁ , Alexander Y Pantelyat ₁₂ , Maria Carmela Tartaglia ₁₃ , Jeffrey L Dage ₁₄ , Adam L Boxer ₁

Affiliation

Department of Neurology, Memory and Aging Center, University of California San Francisco Weill Institute for Neurosciences, University of California, San Francisco.
Lawrence Berkeley National Laboratory, Berkeley, California.
Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Fixel Institute for Neurological Disease, Department of Clinical and Healthy Psychology, University of Florida, Gainesville.
Associate Editor, JAMA Neurology.
Department of Neurology, Mayo Clinic, Rochester, Minnesota.
Frontotemporal Disorders Unit, Massachusetts General Hospital, Boston.
Penn Frontotemporal Degeneration Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Department of Psychiatry, Columbia University, New York, New York.
Department of Neurology, Columbia University, New York, New York.
Department of Neurology, University of California, San Diego.
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
Department of Neurology, Indiana University School of Medicine, Indianapolis.

Plasma phosphorylated tau217 (p-tau217), a biomarker of Alzheimer disease (AD), is of special interest in corticobasal syndrome (CBS) because autopsy studies have revealed AD is the driving neuropathology in up to 40% of cases. This differentiates CBS from other 4-repeat tauopathy (4RT)-associated syndromes, such as progressive supranuclear palsy Richardson syndrome (PSP-RS) and nonfluent primary progressive aphasia (nfvPPA), where underlying frontotemporal lobar degeneration (FTLD) is typically the primary neuropathology.

中文翻译：

评估血浆磷酸化 Tau217 区分阿尔茨海默病和皮质基底节综合征患者额颞叶变性亚型。

血浆磷酸化 tau217 (p-tau217) 是阿尔茨海默病 (AD) 的生物标志物，在皮质基底节综合征 (CBS) 中受到特别关注，因为尸检研究表明 AD 是高达 40% 病例的驱动神经病理学原因。这将 CBS 与其他 4 次重复 tau 蛋白病 (4RT) 相关综合征区分开来，例如进行性核上性麻痹理查森综合征 (PSP-RS) 和不流利的原发性进行性失语症 (nfvPPA)，其中潜在的额颞叶变性 (FTLD) 通常是主要的神经病理学。

更新日期：2023-04-03

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11